Free Trial

Dyadic International (DYAI) Competitors

Dyadic International logo
$1.06
+0.01 (+0.95%)
(As of 10/31/2024 ET)

DYAI vs. CSBR, KPTI, CKPT, RANI, ANVS, TELO, PDSB, ELYM, INMB, and DERM

Should you be buying Dyadic International stock or one of its competitors? The main competitors of Dyadic International include Champions Oncology (CSBR), Karyopharm Therapeutics (KPTI), Checkpoint Therapeutics (CKPT), Rani Therapeutics (RANI), Annovis Bio (ANVS), Telomir Pharmaceuticals (TELO), PDS Biotechnology (PDSB), Eliem Therapeutics (ELYM), INmune Bio (INMB), and Journey Medical (DERM). These companies are all part of the "medical" sector.

Dyadic International vs.

Champions Oncology (NASDAQ:CSBR) and Dyadic International (NASDAQ:DYAI) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, community ranking, profitability, earnings, risk, media sentiment, institutional ownership and valuation.

Champions Oncology has a net margin of -6.58% compared to Dyadic International's net margin of -428.86%. Dyadic International's return on equity of -145.95% beat Champions Oncology's return on equity.

Company Net Margins Return on Equity Return on Assets
Champions Oncology-6.58% -850.72% -12.80%
Dyadic International -428.86%-145.95%-75.92%

Champions Oncology has a beta of 0.46, indicating that its share price is 54% less volatile than the S&P 500. Comparatively, Dyadic International has a beta of 0.73, indicating that its share price is 27% less volatile than the S&P 500.

41.3% of Champions Oncology shares are held by institutional investors. Comparatively, 28.0% of Dyadic International shares are held by institutional investors. 47.0% of Champions Oncology shares are held by insiders. Comparatively, 28.8% of Dyadic International shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Champions Oncology presently has a consensus price target of $6.00, indicating a potential upside of 53.45%. Dyadic International has a consensus price target of $6.00, indicating a potential upside of 466.04%. Given Dyadic International's higher probable upside, analysts plainly believe Dyadic International is more favorable than Champions Oncology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Champions Oncology
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Dyadic International
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Dyadic International has lower revenue, but higher earnings than Champions Oncology. Champions Oncology is trading at a lower price-to-earnings ratio than Dyadic International, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Champions Oncology$50.15M1.06-$7.28M-$0.26-15.04
Dyadic International$1.80M17.18-$6.80M-$0.28-3.79

Dyadic International received 10 more outperform votes than Champions Oncology when rated by MarketBeat users. Likewise, 64.26% of users gave Dyadic International an outperform vote while only 60.24% of users gave Champions Oncology an outperform vote.

CompanyUnderperformOutperform
Champions OncologyOutperform Votes
150
60.24%
Underperform Votes
99
39.76%
Dyadic InternationalOutperform Votes
160
64.26%
Underperform Votes
89
35.74%

In the previous week, Champions Oncology had 1 more articles in the media than Dyadic International. MarketBeat recorded 1 mentions for Champions Oncology and 0 mentions for Dyadic International. Dyadic International's average media sentiment score of 1.89 beat Champions Oncology's score of 1.04 indicating that Dyadic International is being referred to more favorably in the news media.

Company Overall Sentiment
Champions Oncology Positive
Dyadic International Very Positive

Summary

Dyadic International beats Champions Oncology on 9 of the 16 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DYAI vs. The Competition

MetricDyadic InternationalBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$30.99M$3.16B$5.36B$8.41B
Dividend YieldN/A1.77%5.22%4.20%
P/E Ratio-3.7916.48131.9317.57
Price / Sales17.18343.231,440.1578.36
Price / CashN/A139.6939.0633.56
Price / Book5.303.904.744.57
Net Income-$6.80M-$40.42M$115.43M$225.42M
7 Day Performance-4.33%-0.16%-0.86%-0.61%
1 Month Performance1.92%3.45%3.61%1.50%
1 Year Performance-34.57%32.76%38.90%32.94%

Dyadic International Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DYAI
Dyadic International
2.5552 of 5 stars
$1.06
+1.0%
$6.00
+466.0%
-34.8%$30.99M$1.80M-3.797Positive News
Gap Up
CSBR
Champions Oncology
4.197 of 5 stars
$3.91
+3.2%
$6.00
+53.5%
-32.8%$53.14M$50.15M-15.04143Short Interest ↓
Positive News
Gap Up
KPTI
Karyopharm Therapeutics
4.3941 of 5 stars
$0.99
+17.9%
$5.00
+405.2%
+2.5%$123.35M$145.67M-0.84380Upcoming Earnings
Short Interest ↓
News Coverage
Gap Up
High Trading Volume
CKPT
Checkpoint Therapeutics
3.5528 of 5 stars
$3.44
-5.0%
$12.00
+248.8%
+91.5%$122.76M$78,000.00-1.8110Short Interest ↑
High Trading Volume
RANI
Rani Therapeutics
3.2116 of 5 stars
$2.29
-1.3%
$11.71
+411.5%
+18.4%$122.30M$2.72M-1.94110Positive News
ANVS
Annovis Bio
2.1401 of 5 stars
$9.30
-2.6%
$32.17
+245.9%
+17.7%$121.40MN/A-1.823Short Interest ↑
TELO
Telomir Pharmaceuticals
N/A$4.06
-7.9%
N/AN/A$120.22MN/A0.001Positive News
PDSB
PDS Biotechnology
1.0554 of 5 stars
$3.19
-0.6%
$14.25
+346.7%
-23.5%$117.46MN/A-2.6120
ELYM
Eliem Therapeutics
N/A$3.92
-3.0%
N/A+51.4%$116.63MN/A-7.4020
INMB
INmune Bio
2.477 of 5 stars
$5.85
-1.7%
$20.00
+241.9%
-12.0%$115.60M$85,000.00-2.8410Short Interest ↑
News Coverage
DERM
Journey Medical
3.7373 of 5 stars
$5.75
+0.5%
$9.38
+63.0%
N/A$115.08M$77.68M-287.5090Upcoming Earnings
Short Interest ↓

Related Companies and Tools


This page (NASDAQ:DYAI) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners